GSEP
ORKA

Golden State Equity Partners’s Oruka Therapeutics ORKA Stock Holding History

Golden State Equity Partners’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8
Closed -$392 – 1842
2026
Q1 		$392 Buy
+8
New +$278 ﹤0.01% 1913

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Golden State Equity Partners's ORKA Position: Q2 2026 in Review

Golden State Equity Partners sold out of Oruka Therapeutics (ORKA) in Q2 2026, closing a stake of 8 shares — an estimated $392 sold.

Golden State Equity Partners first reported a position in ORKA in Q1 2026 and held it in 1 quarter. The position peaked at $392 in Q1 2026. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Golden State Equity Partners reported no remaining Oruka Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 8 Oruka Therapeutics shares in Q2 2026, an estimated $392.
  • Golden State Equity Partners first reported a position in Oruka Therapeutics in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Oruka Therapeutics position peaked at $392 in Q1 2026.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.